Flag of the European Union EU Clinical Trials Register Help

Clinical trials for vinorelbine tartrate

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    37 result(s) found for: vinorelbine tartrate. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2004-000963-81 Sponsor Protocol Number: PM0259CA221B0 Start Date*: 2004-11-15
    Sponsor Name:Robapharm AG
    Full Title: A Randomised Phase II study of Oral Vinorelbine or I.V. Vinorelbine in patients with metastatic breast cancer previously treated with anthracyclines
    Medical condition: Treatment in metastatic breast cancer previously treated with anthracyclines
    Disease:
    Population Age: Elderly Gender: Female
    Trial protocol: AT (Completed) BE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-004105-16 Sponsor Protocol Number: MO29872 Start Date*: 2017-12-11
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A PHASE III, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB COMPARED WITH CHEMOTHERAPY IN PATIENTS WITH TREATMENT-NAÏVE ADVANCED OR RECURRENT (STAG...
    Medical condition: Non-small cell lung cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029522 Non-small cell lung cancer stage IV PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059515 Non-small cell lung cancer metastatic PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029515 Non-small cell lung cancer recurrent PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) DK (Completed) CZ (Completed) GB (GB - no longer in EU/EEA) PT (Completed) PL (Completed) ES (Ongoing) IE (Completed) BE (Completed) SK (Completed) BG (Completed) IT (Completed) RO (Ongoing)
    Trial results: View results
    EudraCT Number: 2004-001904-10 Sponsor Protocol Number: PM0259CA301J1 Start Date*: 2004-09-15
    Sponsor Name:Pierre Fabre Médicament represented by IRPF
    Full Title: Prospective randomised clinical phase III trial of (alternating IV and oral) vinorelbine plus cisplatin versus docetaxel plus cisplatin in first line chemotherapy of locally advanced or metastatic ...
    Medical condition: Treatment in locally advanced or metastatic non-small-lung cancer.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) EE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-005135-26 Sponsor Protocol Number: PM0259 CA304 J1 Start Date*: 2005-05-02
    Sponsor Name:Pierre Fabre Médicament
    Full Title: ORAL VINORELBINE AND CISPLATIN WITH CONCOMITANT RADIOTHERAPY FOLLOWED BY EITHER CONSOLIDATION THERAPY WITH ORAL VINORELBINE AND CISPLATIN PLUS BEST SUPPORTIVE CARE OR BEST SUPPORTIVE CARE ALONE IN ...
    Medical condition: Stage III Non small cell lung cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-003859-61 Sponsor Protocol Number: PM0259CA232J1 Start Date*: 2015-07-28
    Sponsor Name:PIERRE FABRE MEDICAMENT
    Full Title: Randomized Phase II study comparing single agent oral vinorelbine administered with two different schedules in patients with Advanced Non Small Cell Lung Cancer unfit for a platinum-based chemotherapy
    Medical condition: Advanced Non Small Lung Cancer unfit for a platinium-based chemotherapy
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) PL (Completed) HU (Completed) CZ (Completed) DE (Completed) AT (Completed) FR (Completed) GR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2004-000753-30 Sponsor Protocol Number: PM0259CA219B0 Start Date*: 2004-11-08
    Sponsor Name:Pierre Fabre Ibérica S.A. as legal representative of Pierr Fabre Mèdicament
    Full Title: Phase II trial of oral vinorelbine in combination with capecitabine as first line therapy in women with previously untreated HER2 negative metastatic breast cancer.
    Medical condition: Treatment in women with previously untreated HER2 negative metastatic breast cancer.
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2004-000602-44 Sponsor Protocol Number: NVB CA 03 P SP 102 B0 Start Date*: 2004-09-28
    Sponsor Name:Pierre Fabre Ibérica, S.A.
    Full Title: Ensayo clínico en fase I-II de vinorelbina oral (Navelbine) en combinación con capecitabina en tratamiento de primera línea en pacientes con cáncer de mama avanzado
    Medical condition: Advanced breast cancer (metastatic)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2004-000748-26 Sponsor Protocol Number: PM0259CA215B0 Start Date*: 2004-11-08
    Sponsor Name:Pierre Fabre Ibérica, S.A. en representación de Pierre Fabre Mèdicament
    Full Title: Phase II trial of oral vinorelbine in combination with capecitabine and trastuzumab as first line therapy in women with previously untreated HER2 positive metastatic breast cancer.
    Medical condition: Treatment in women with previously untreated HER2 positive metastatic breast cancer.
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2012-003530-16 Sponsor Protocol Number: PM0259CA231B0 Start Date*: 2012-11-14
    Sponsor Name:PIERRE FABRE MEDICAMENT
    Full Title: Randomised phase II study evaluating, as first-line chemotherapy, weekly oral vinorelbine as a single-agent versus weekly paclitaxel as a single-agent in estrogen receptor positive, HER2 negative p...
    Medical condition: advanced breast cancer with estrogen receptor positive and HER2 negative.
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: AT (Completed) ES (Completed) PL (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2012-003531-40 Sponsor Protocol Number: PM259CA230J1 Start Date*: 2012-12-20
    Sponsor Name:Pierre Fabre Medicament
    Full Title: Randomised phase II trial of oral vinorelbine and cisplatin followed by maintenance with single agent oral vinorelbine versus gemcitabine and cisplatin followed by maintenance with single agent gem...
    Medical condition: First line Locally Advanced or Metastatic Non-Small-Cell Lung Cancer patients with squamous histological type
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) IT (Completed) AT (Completed) PL (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2004-005205-30 Sponsor Protocol Number: PM0259CA222B0 Start Date*: 2006-09-06
    Sponsor Name:Pierre Fabre Medicament
    Full Title: Randomised phase II study of the combination of oral vinorelbine with capecitabine versus a sequential regimen of oral vinorelbine and capecitabine versus the combination of docetaxel and capecitab...
    Medical condition: Patients with metastatic breast cancer previously treated with anthracyclines
    Disease: Version SOC Term Classification Code Term Level
    7.1 10027475 LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2004-000962-11 Sponsor Protocol Number: PM0259CA217B0 Start Date*: 2005-03-01
    Sponsor Name:Pierre Fabre Medicament represented by IRPF
    Full Title: Phase II Study of Navelbine oral and Arimidex as neo-adjuvant treatment in post-menopausal women with locally advanced breast carcinoma
    Medical condition: Neo-Adjuvant Treatment in Post-menopausal women with locally advanced breast carcinoma.
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: CZ (Completed)
    Trial results: View results
    EudraCT Number: 2019-004987-23 Sponsor Protocol Number: RAS-Triplet Start Date*: 2020-05-22
    Sponsor Name:UMC Utrecht
    Full Title: A Dose-Escalating Phase I/II Study in Patients with RAS-Mutated Metastatic Colorectal Cancer to Investigate Safety and Clinical Activity of the Triple Combination of: MEK-inhibitor binimetinib, Pan...
    Medical condition: colorectal cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-001992-30 Sponsor Protocol Number: Start Date*: 2015-04-20
    Sponsor Name:University of Leicester
    Full Title: A randomised controlled phase II trial of oral vinorelbine as second line therapy for patients with malignant pleural mesothelioma
    Medical condition: Histologically confirmed malignant pleural mesothelioma
    Disease: Version SOC Term Classification Code Term Level
    17.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059518 Pleural mesothelioma malignant PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2014-003860-19 Sponsor Protocol Number: PM0259CA233B0 Start Date*: 2015-09-07
    Sponsor Name:PIERRE FABRE MEDICAMENT
    Full Title: Randomised Phase II Study comparing, as first-line chemotherapy, single-agent Oral Vinorelbine administered with two different schedules in patients with Advanced Breast Cancer.
    Medical condition: Advanced Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Completed) ES (Completed) AT (Completed) HU (Completed) RO (Completed) CZ (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2012-003361-18 Sponsor Protocol Number: PM0259CA229J1 Start Date*: 2013-01-24
    Sponsor Name:PIERRE FABRE MEDICAMENT
    Full Title: Phase II trial of oral vinorelbine in Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) patients with Epidermal Growth Factor Receptor (EGFR) positive mutation after a failure to tr...
    Medical condition: Patients with: -Histologically or cytologically confirmed NSCLC (stage IIIB or IV) and -epidermal growth factor receptor (EGFR) positive mutation and -previously treated with tyrosine kinase inhibi...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029522 Non-small cell lung cancer stage IV PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029521 Non-small cell lung cancer stage IIIB PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029515 Non-small cell lung cancer recurrent PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2016-000284-17 Sponsor Protocol Number: VinoMetro2015-007 Start Date*: 2016-11-11
    Sponsor Name:Universitätsmedizin Mainz
    Full Title: Phase II study of metronomic treatment with daily oral vinorelbine as first-line chemotherapy in patients with advanced/metastatic HR+/HER2- breast cancer resistant to endocrine therapy (VinoMetro).
    Medical condition: HR+/HER2- advanced/metastatic breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-007885-39 Sponsor Protocol Number: 3144A1-2204-WW Start Date*: 2008-05-27
    Sponsor Name:Wyeth Research Division of Wyeth Pharmaceuticals Inc.
    Full Title: A Phase I/II Study of HKI-272 in Combination With Vinorelbine in Subjects With Solid Tumors and Metastatic Breast Cancer.
    Medical condition: Solid tumors (part 1) and metastatic breast cancer (part 2).
    Disease: Version SOC Term Classification Code Term Level
    13.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) PL (Completed) FR (Completed) NL (Completed) GB (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2008-003779-37 Sponsor Protocol Number: IOM-080-2 Start Date*: 2009-02-05
    Sponsor Name:iOMEDICO AG
    Full Title: Capecitabine and bevacizumab ± vinorelbine as 1st line treatment in HER2/neu-negative metastatic or locally advanced inoperable breast cancer patients
    Medical condition: HER-2/neu negative metastatic or locally advanced inoperable breast cancer
    Disease: Version SOC Term Classification Code Term Level
    17.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006202 Breast cancer stage IV PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2004-000665-35 Sponsor Protocol Number: PM0259CA220B0 Start Date*: 2004-09-08
    Sponsor Name:Pierre Fabre Medicament
    Full Title: Phase II study of oral vinorelbine in combination with capecitabine in metastatic breast cancer patients previously treated with anthracyclines and taxanes
    Medical condition: Treatment in metastatic breast cancer women previously treated with anthracyclines and taxanes
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 01 06:38:55 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA